Tagged with STrategy

Canada Michel Fortin, president and CEO of Prevtec Microbia, a global biotech player founded in Saint-Hyacinthe, outside of Montréal, analyzes the opportunities in the global animal health industry, and how Prevtec Microbia has positioned itself to seize those by developing technologies that are alternatives to the usage of antibiotics in animal…

Poland Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore, he highlights the strategic importance of Poland in the region as the company’s footprint continues to grow and highlights the…

Lithuania Janis Kalejs, country manager Baltics at Mylan, discloses the strategies he has used to successfully lead his affiliate through corporate changes and explains how Mylan aims to continue providing affordable as well as high-quality treatments to patients in the region. What is the history of Mylan in the Baltics? “The…

Brazil Armando Correa Lopes Jr, managing director of Siemens Healthineers Brazil, provides insights into the main trends and challenges at the core of Brazil’s healthcare discussion and documents the contribution of Siemens Healthineers in shaping a more cost-efficient, value-based, and data-oriented Brazilian model of healthcare. Leveraging your long-standing experience of Brazil’s…

Serbia Ljubiša Mitof-Višurski, general manager for AbbVie Adria, discusses the main challenges, opportunities and synergies the Adria region has to offer. He underlines the key healthcare initiatives AbbVie engages with in the region, as well as the crucial role the company plays in bringing innovative solutions to patients. Can you provide…

Lithuania Raimundas Voishka, country manager Lithuania and Belarus at Pfizer, highlights the increasing openness of the Baltic region towards innovation and stresses the commitment of Pfizer to bringing innovative as well as added-value medicines to the region. You have more than 20 years of experience in the Lithuanian pharmaceutical industry. What…

Serbia Milos Davidovic, Mylan’s country manager responsible for Serbia, Slovenia, Macedonia, and Montenegro, reveals the made-to-measure market approach that he has been implementing in the region for the past six years while highlighting the crucial role of employing a highly educated, expert workforce. What potential did Mylan see in Serbia, and…

Serbia Founder and general director of INNventa, Goran Orlic, discusses the rationale behind establishing his own company that continues to double revenues year on year. He highlights the company’s fundamental role in providing innovative solutions to Serbian patients, pharmacists and doctors. Finally, he discusses investment opportunities in the Balkans, underlining the…

Poland Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to…

Brazil Fernando Itzaina, president and CEO of FQM Group, originally Farmoquímica, provides inspiring insights into the threefold development vision favored by this rapidly growing pharmaceutical company, his commitment to continue exploring both organic and inorganic growth options in order to better service Brazilian patients and physicians, as well as FQM’s enduring…

Canda Richard Lajoie shares his main priorities for his tenure as new president of Valeant’s Canadian operations: portfolio rejuvenation through launches of innovative molecules addressing the unmet needs of Canadian patients, growing the company’s manufacturing capacity in the country and fostering the Valeant culture. What does Canada represent for Valeant today?…

Lithuania Marius Giedraitis, director and founder of Balux, explains the company’s commitment to shipping high-value temperature-sensitive pharmaceuticals with quality goals of 99.5 percent of deliveries without any deviation by 2019. Could you please introduce the main activities and operations of Balux to our international audience? “Our niche strategy helps us to…